From: Telomerase reverse transcriptase gene amplification in hematological malignancies
Parameter | B-NHL patients (N = 15) |
---|---|
Age (mean ± SD) | 64.3 ± 7.4 |
Gender, N (%) | |
Male | 9 (60%) |
Female | 6 (40%) |
Presentation, N (%) | |
DNV | 12 (80%) |
Relapse | 3 (20%) |
Lymphadenopathy, N (%) | 15 (100%) |
Splenomegaly, N (%) | 10 (66.7%) |
Hepatomegaly, N (%) | 6 (40%) |
WBC count (× 109/l) (mean ± SD) | 13.5 ± 9.5 |
Hb level (g/dl) (mean ± SD) | 11.4 ± 2.9 |
Platelet count (× 109/l) (mean ± SD) | 154 ± 65 |
BM lymphocytes % (mean ± SD) | 52.5 ± 20 |
Lactate dehydrogenase (U/l) (mean ± SD) | 277.3 ± 73 |
Karyotype, N (%) | |
Normal | 8 (53.3%) |
Numerical aberrations | 5 (33.3%) |
Structural aberrations | 2 (13.3%) |
P53 (17p13.1) deletion, N (%) | 5 (33.3%) |
14q32 rearrangement, N (%) | 3 (20%) |
TERT amplification, N (%) | 7 (46.7%) |
Prognosis, N (%) | |
I | 6 (40%) |
II | 2 (13.3%) |
III | 7 (46.7%) |